Pirtobrutinib Maintains Efficacy and Decreases BTK C481 Clones Despite Acquired Resistance Mutations in CLL

Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.

Related Keywords

,International Workshop ,Cll ,Chronic Lymphocytic Leukemia ,Leukemia ,Btk Inhibitor Resistance ,International Workshop On Cll ,Iwcll ,Mutations ,Phase 1 2 Bruin Trial Nct03740529 ,Non C481 Clones ,Pirtobrutinib ,Btk Cysteine 481 ,